|Rodman & Renshaw Capital Group, Inc. Expands Equity Research Department With the Addition of Five Senior Analysts|
NEW YORK, Mar 29, 2010 (BUSINESS WIRE) --Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), today highlights the expansion of the firm's equity research group with the recent addition of five senior analysts, expanding Rodman & Renshaw's coverage in key sectors including Technology, Medical Devices, Specialty Pharmaceuticals and Banking, as well as geographically with the expansion of its China focused research team. Following these additions Rodman & Renshaw now has 12 senior analysts.
Edward Rubin, Rodman & Renshaw's Chief Executive Officer commented on the occasion, "These strategic additions to our research team represent Rodman & Renshaw's commitment to expanding and strengthening the firm's equity research franchise in our core areas of focus. The exceptional levels of experience these individuals bring to the team significantly enhance our ability to identify and analyze only the very best ideas for the benefit of our clients."
Recent Additions to Rodman & Renshaw's Equity Research Department Include:
Ashok Kumar joins Rodman & Renshaw as Managing Director and Senior Technology Analyst. Previously Mr. Kumar was the head of technology research at Northeast Securities and Collins Stewart. He has held senior analyst positions with Raymond James and Piper Jaffray and was also an analyst at Prudential Securities. Mr. Kumar's professional career includes engineering and marketing positions at Intel. He is frequently quoted in publications such as The Wall Street Journal, The New York Times, and is regularly featured on CNBC and Bloomberg. He was named to Smart Money magazine's 30 Most Influential People in Investing in December of 2000.
Lewis Fan joins Rodman & Renshaw as Managing Director and Senior China Analyst. Prior to joining Rodman, Mr. Fan was the Chief Financial Officer of China-Biotics, Inc. Before that, he was a senior analyst at Brean Murray, Carret covering small cap Chinese companies. Mr. Fan also served as an equity analyst at UBS covering large cap biotech and as an emerging markets strategist at Deutsche Bank. Mr. Fan's opinions have been cited in a wide variety of media such as Washington Post, Investor's Business Daily, DWNews, PharmAsia News, and theStreet.com TV.
Suraj Kalia rejoins Rodman & Renshaw as Managing Director and Senior Medical Device Analyst. Mr. Kalia has more than 15 years of experience working in the financial and health care industries. He joins Rodman from Sanders Morris Harris where he had primary coverage responsibility for the medical devices sector. Prior to Sanders Morris, Mr. Kalia has been a Senior Device Analyst at Piper Jaffray and Rodman & Renshaw. He was ranked first by Forbes.com/Starmine and ranked in the top five of the Wall Street Journal's 2005 "Best on the Street" survey in the medical devices sector. Before his sell-side career, Mr. Kalia spent seven years at Entegris, Inc. as part of the mergers and acquisitions group.
Michael Higgins rejoins Rodman & Renshaw as Managing Director and Senior Specialty Pharmaceuticals Analyst. Prior to joining the firm, Mr. Higgins gained ten years of drug marketing experience with Procter & Gamble Pharmaceuticals, followed by seven years as a research analyst. His analyst experience includes working for Dafna Capital Management, Wedbush Morgan Securities and an independent research firm he founded, 4sight Research Partners, LLP.
Douglas Rainwater joins Rodman & Renshaw as Managing Director and Senior Bank Analyst. Mr. Rainwater has 15 years of experience in banking and financial services and has previously held positions as a banking research analyst with Janney Montgomery Scott and Stanford Group Company. Prior to his research career, Mr. Rainwater spent six years as an investment banker with regional investment banking firms including Morgan Keegan & Co. and Sterne Agee, where he assisted community and regional banks with mergers and acquisitions as well as capital offerings.
About Rodman & Renshaw, LLC
Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of deal volume of PIPE and RD financing transactions completed every year since 2005. For more information please visit: http://www.rodm.com
MEMBER FINRA, SIPC
SOURCE: Rodman & Renshaw, LLC
Rodman & Renshaw Investor Relations